Salarius Pharmaceuticals, Inc. (SLRX) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
SLRX Insider Trading Activity
SLRX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Insider Activity of Salarius Pharmaceuticals, Inc.
Over the last 12 months, insiders at Salarius Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Salarius Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Salarius Pharmaceuticals, Inc. have bought $44,742 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 37,500 shares for transaction amount of $7,016 was made by Lieber Jonathan I () on 2022‑06‑07.
List of Insider Buy and Sell Transactions, Salarius Pharmaceuticals, Inc.
| 2022-06-07 | Lieber Jonathan I | 37,500 0.0703% | $0.19 | $7,016 | -53.27% | |||
| 2022-06-07 | Burleson Tess | 27,700 0.0499% | $0.18 | $4,986 | -53.27% | |||
| 2022-06-06 | McVicar William K. | 26,553 0.0492% | $0.19 | $5,000 | -53.68% | |||
| 2022-06-03 | HANISH ARNOLD C | 28,000 0.0521% | $0.18 | $5,152 | -52.08% | |||
| 2022-05-31 | Rosenblum Mark J | Exec VP Finance, CFO | 28,000 0.0522% | $0.18 | $5,040 | -50.75% | ||
| 2022-05-26 | Arthur David J. | Chief Executive Officer | 10,800 0.0206% | $0.18 | $1,990 | -50.53% | ||
| 2022-03-03 | Arthur David J. | Chief Executive Officer | 139,488 0.3016% | $0.39 | $54,540 | -51.33% | ||
| 2022-03-03 | Rosenblum Mark J | Exec VP Finance, CFO | 76,246 0.1648% | $0.39 | $29,812 | -51.33% | ||
| 2021-08-17 | Arthur David J. | Chief Executive Officer | 4,000 0.0091% | $0.90 | $3,582 | -49.84% | ||
| 2021-08-10 | HANISH ARNOLD C | director | 7,000 0.0156% | $0.88 | $6,167 | -48.23% | ||
| 2020-08-21 | HANISH ARNOLD C | director | 4,000 0.0226% | $0.98 | $3,920 | +10.72% | ||
| 2020-08-19 | Arthur David J. | Chief Executive Officer | 2,000 0.011% | $1.01 | $2,020 | +4.41% | ||
| 2020-08-17 | Rosenblum Mark J | Exec VP Finance, CFO | 5,000 0.0282% | $1.00 | $5,000 | +7.79% | ||
| 2020-02-19 | Rosenblum Mark J | Exec VP Finance, CFO | 2,000 0.0208% | $0.95 | $1,900 | -5.19% | ||
| 2020-02-18 | Jordan Scott | Chief Business Officer | 11,300 0.1185% | $0.90 | $10,170 | +1.11% | ||
| 2020-02-13 | Rosenblum Mark J | Exec VP Finance, CFO | 5,000 0.0506% | $0.86 | $4,295 | +0.72% | ||
| 2020-02-11 | Northrup Jonathan P | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% | ||
| 2020-02-11 | Arthur David J. | Chief Executive Officer | 2,175 0.0314% | $1.15 | $2,501 | +6.95% | ||
| 2020-02-11 | McVicar William K. | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% | ||
| 2020-02-11 | McCreedy Bruce J Jr. | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% |
Insider Historical Profitability
| Boston Foundation, Inc. | 10 percent owner | 1600000 75.213% | $1.39M | 0 | 2 | |
| MacKinnon Roderick | director | 431277 20.2735% | $375,167.86 | 1 | 0 | |
| Northrup Jonathan P | director | 352713 16.5804% | $306,825.04 | 1 | 0 | +6.95% |
| Arthur David J. | Chief Executive Officer | 303574 14.2705% | $264,079.02 | 5 | 0 | <0.0001% |
| Rosenblum Mark J | Exec VP Finance, CFO | 148319 6.9722% | $129,022.70 | 5 | 0 | <0.0001% |
| Wessel Thomas | Chief Medical Officer | 57064 2.6825% | $49,639.97 | 2 | 0 | |
| HANISH ARNOLD C | 46350 2.1788% | $40,319.87 | 5 | 0 | <0.0001% | |
| Lieber Jonathan I | 37500 1.7628% | $32,621.25 | 1 | 0 | <0.0001% | |
| Burleson Tess | 32050 1.5066% | $27,880.30 | 2 | 0 | <0.0001% | |
| Jordan Scott | Chief Business Officer | 31609 1.4859% | $27,496.67 | 1 | 0 | +1.11% |
| McVicar William K. | 26553 1.2482% | $23,098.45 | 2 | 0 | <0.0001% | |
| McCreedy Bruce J Jr. | director | 8700 0.409% | $7,568.13 | 1 | 0 | +6.95% |
| SCULLEY JOHN | director | 4709 0.2214% | $4,096.36 | 2 | 0 | |
| KOZIN MARC D | director | 4500 0.2115% | $3,914.55 | 1 | 0 | |
| Stacy Michelle | director | 2585 0.1215% | $2,248.69 | 1 | 0 | |
| McCabe John P. | VP of Finance & Treasurer | 1650 0.0776% | $1,435.34 | 1 | 0 | |
| Westphal Christoph H | 10 percent owner | 0 0% | $0 | 80 | 1 | |
| Longwood Fund II, L.P. | 10 percent owner | 0 0% | $0 | 2 | 1 |
Historical Insider Profitability vs. Competitors
$13,665,147 | 42 | -70.74% | $3.08M | |
$1,138,733 | 28 | -4.94% | $3.5M | |
$41,829 | 26 | -15.60% | $3.75M | |
Salarius Pharmaceuticals, Inc. (SLRX) | $193,112 | 22 | -20.59% | $1.85M |
$1,616,354 | 20 | -12.22% | $4M | |
$613,181 | 18 | -20.90% | $2.78M | |
$960,082 | 17 | -6.29% | $4.2M | |
$111,212 | 12 | -28.79% | $3.26M | |
$4,146,041 | 11 | -40.86% | $1.14M | |
$139,855 | 11 | -32.84% | $3.6M | |
$309,830 | 10 | -55.78% | $3.97M | |
$100,375 | 8 | -51.85% | $4.06M | |
$159,974 | 7 | -18.60% | $1.58M | |
$115,514 | 4 | -94.89% | $4.17M | |
$37,465 | 3 | -40.67% | $2.76M | |
$1,057,000 | 3 | 5.27% | $3.7M | |
$37,067 | 3 | -89.81% | $3.35M | |
$552,301 | 2 | -80.60% | $755,928.00 | |
$165,600 | 2 | -3.58% | $3.34M |
SLRX Institutional Investors: Active Positions
| Increased Positions | <1 | +10% | 6,821 | +129.97% |
| Decreased Positions | 3 | -30% | 4,806 | -91.58% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 2 | Sold Out | 4,799 | Sold Out |
| Total Postitions | 8 | -20% | 7,263 | +38.4% |
SLRX Ownership Change vs Market
Institutional Investor Ownership
| Ubs Group Ag | $5.00 | 0.35% | 7,081 | +6,821 | +2,623.46% | 2024-12-31 |
| Osaic Holdings, Inc. | $0 | 0.01% | 162 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | <0.01% | 11 | -7 | -38.89% | 2024-12-31 |
| Morgan Stanley | $0 | 0% | 7 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $0 | 0% | 1 | 0 | 0% | 2025-03-31 |
| Sbi Securities Co., Ltd. | $0 | 0% | 1 | 0 | 0% | 2025-03-31 |
| Citigroup Inc | $0 | 0% | 0 | -1,610 | Sold Out | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $0 | 0% | 0 | -3,189 | Sold Out | 2024-12-31 |